Pacira BioSciences, Inc. (NASDAQ: PCRX) has disclosed recent insider trading activity involving its Chief Financial Officer, Shawn Cross. Between April 20 and April 22, 2026, Mr. Cross executed the sale of 12,059 shares of company common stock, resulting in total proceeds of $302,598.
The divestments were carried out at price points ranging from $25.01 to $25.14 per share. This pricing range sits slightly above the current market valuation of $24.88 per share. These trades were not spontaneous; rather, they were performed in accordance with a Rule 10b5-1 trading plan that Mr. Cross had previously adopted on June 9, 2025.
The Mechanics of the Transaction
Prior to the sale, Mr. Cross acquired the 12,059 shares through the exercise of stock options. The cost to acquire these shares via option exercise was $16.45 per share, amounting to a total acquisition value of $198,370. The structure of these options included a vesting schedule where 25% vested on the first anniversary of the grant date, with the remaining portion vesting in equal quarterly installments over the following three years, contingent upon Mr. Cross maintaining continuous service with Pacira BioSciences.
Following the completion of these transactions, Shawn Cross maintains a direct holding of 105,341 shares of Pacira BioSciences common stock.
Market Context and Financial Performance
The movement in PCRX stock occurs against a backdrop of varying performance metrics. Over the previous six months, the stock has generated a 15% return and is currently trading near its 52-week high of $27.64. Despite this recent momentum, analysis from InvestingPro suggests the company may be undervalued, noting that shares are currently trading below their calculated Fair Value.
However, recent financial reporting has highlighted challenges for the firm. In its fourth-quarter 2025 earnings report, Pacira BioSciences missed expectations on key metrics. The reported earnings per share (EPS) was $0.57, failing to meet the anticipated $0.90. Additionally, revenue for the quarter reached $196.9 million, which was below the projected $200.54 million.
Governance and Shareholder Activism
Pacira BioSciences is also facing significant pressure from DOMA Perpetual Capital Management LLC, a shareholder holding approximately 7.3% of the company's common stock. DOMA has nominated three individuals to be elected to the company's board at the upcoming 2026 annual meeting of stockholders. Furthermore, the group has called for the removal of CEO Frank Lee, citing long-term poor financial performance.
The company has acknowledged these nominations and confirmed that management and the board have engaged in multiple discussions with DOMA since Mr. Lee assumed the role of CEO in January 2024. Pacira BioSciences maintains that DOMA has not presented any new operational or strategic insights beyond the existing plans being evaluated and implemented by the current leadership team.
Key Analysis Points
- Executive Liquidity: The use of a Rule 10b5-1 plan allows executives to sell shares according to a predetermined schedule, which can mitigate concerns regarding the timing of trades relative to non-public information.
- Financial Divergence: There is a notable gap between the stock's recent 15% return and its recent quarterly misses in revenue and EPS.
- Governance Risk: The push by DOMA Perpetual Capital Management for board changes and leadership removal introduces uncertainty into the company's strategic direction.
Risks and Uncertainties
- Earnings Volatility: The miss on both top-line revenue and bottom-line EPS in Q4 2025 suggests potential volatility in meeting future financial targets, impacting the healthcare and biotech sectors.
- Leadership Transition Risk: The active campaign by a major shareholder to remove the CEO and reshape the board creates uncertainty regarding management stability and corporate strategy.